Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

PHARMAUST LIMITED

ABN

35 094 006 023

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

+Class of +securities issued or to be issued

Fully Paid Ordinary Shares

Unlisted Options

Number of *securities issued or to be issued (if known) or maximum number which may be issued Consolidation of 1,840,069,106 Fully Paid Ordinary Shares to 92,003,645 on a 20 for 1 basis.

Consolidation of 8,500,000 Unlisted Options to 425,000 on a 20 for 1 basis

Issue of 250,000 Unlisted Options (postconsolidation)

Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

The consolidation was achieved through the conversion of 20 shares into 1 share and 20 options into 1 option as approved by shareholders at the Company's AGM held on 27 October 2015

Unlisted Options
Exercise Price \$0.16
Expiry Date 3 September 2018

⁺ See chapter 19 for defined terms.

\bigcirc
2

4 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

N/a

Yes

250,000 Unlisted Options issued for nil consideration as approved by shareholders at the Company's AGM held on 27 October 2015

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) Share consolidation

250,000 Unlisted Options issued for nil consideration as approved by shareholders at the Company's AGM held on 27 October 2015

6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

res

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

27 October 2015

Appendix 3B Page 2 01/08/2012

⁺ See chapter 19 for defined terms.

6c	Number of *securities issued without security holder approval under rule 7.1	Nil	
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of securities issued under an exception in rule 7.2	Nil	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	Nil	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Nil	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	10 November 2015	
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	Number 92,003,645	+Class Fully Paid Ordinary Shares

⁺ See chapter 19 for defined terms.

9	Number	and	+class	of	all
	+securities	not	quoted	on A	ASX
	(including	the	secur	ities	in
	section 2 i	f appl	icable)		

Number	+Class
675,000	Unlisted Options Ex \$0.16 Expiry 3/9/18

Dividend policy (in the case of a 10 trust, distribution policy) on the increased capital (interests)

The Company does not expect to pay a dividend this period.

Part 2 - Bonus issue or pro rata issue

- 11 Is security holder approval N/A required? Is the issue renounceable or non-N/A 12
- renounceable?
- Ratio in which the *securities will N/A 13 be offered
- ⁺Class of ⁺securities to which the N/A offer relates
- ⁺Record 15 date to determine N/A entitlements
- 16 Will holdings on different N/A registers (or subregisters) be aggregated calculating for entitlements?
- Policy for deciding entitlements N/A 17 in relation to fractions
- 18 Names of countries in which the entity has +security holders who will not be sent new issue documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

Closing date for receipt acceptances or renunciations

N/A

N/A

19

Appendix 3B Page 4 01/08/2012

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee	N/A
	or commission	
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
	TT 1 ± 1. 1.11 11	[N//A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
21	How do *security holders sell <i>part</i>	N/A
31	of their entitlements through a broker and accept for the balance?	

⁺ See chapter 19 for defined terms.

Appendix	3B
New issue	announcement

32	of the	do *security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	⁺ Desp	oatch date	N/A
	•	notation of securities complete this section if you are app	
34	Type (tick o	of securities one)	
(a)		Securities described in Part	I
(b)		*	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entitie	s that	have ticked box 34(a)	
Additi	onal s	ecurities forming a new	class of securities
Tick to docum		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the he number and percentage of additional *securities
36			securities, a distribution schedule of the additional umber of holders in the categories
37		A copy of any trust deed for	the additional *securities

Appendix 3B Page 6 01/08/2012

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)				
38	Number of securities for which ⁺ quotation is sought			
39	Class of *securities for which quotation is sought			
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment			
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)			
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)	Number	+Class	

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: _______5 November 2015

(Director & Company Secretary)

Sam Wright

Print name:

Appendix 3B Page 8 01/08/2012

⁺ See chapter 19 for defined terms.

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	92,003,645	
 Add the following: Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 		
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period		
"A"	92,003,645	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	-
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	13,800,547
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rul
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	nil
• Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	nil
Step 4: Subtract "C" from ["A" x ' placement capacity under rule 7.1	-
"A" x 0.15	92,003,645
Note: number must be same as shown in Step 2	
Subtract "C"	nil
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	92,003,645
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 10 01/08/2012

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in	92,003,645	
Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	9,200,365	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
Notes: This applies to equity securities – not		
just ordinary securities		
Include here – if applicable – the securities the subject of the Appendix		
3B to which this form is annexedDo not include equity securities issued		
under rule 7.1 (they must be dealt with in Part 1), or for which specific security		
holder approval has been obtainedIt may be useful to set out issues of		
securities on different dates as separate line items		
"E"	Nil	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	9,200,365	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	9,200,365	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 12 01/08/2012

⁺ See chapter 19 for defined terms.